Shire to Massachusetts: Pass incentive bill now

The Massachusetts Legislature is taking its sweet time passing Governor Deval Patrick's proposed $1 billion incentive bill, and Shire is not too happy about it. The U.K.-based drug company was planning to build a $210 million plant in the state, but Shire is now threatening to take its business (and the 600 jobs it would create) elsewhere unless the state government passes the incentive package. North Carolina in particular is angling to attract Shire's business.

Back in July, Massachusetts Governor Patrick (D) filed a 10-year, $1 billion biotech investment bill designed to help the state keep its lead in the industry. The proposal included $25 million in tax incentives to attract pharmaceutical and biotech companies to Massachusetts. However, the bill is currently cooling its heels in the state's House of Representatives, which has yet to start the review process. "The process has been somewhat slower than what we originally anticipated," said a Shire spokesperson. The life science economic development world is cutthroat, and Massachusetts can't afford to drag its feet.

- see this article

Related Articles:
Mass. announces $1B stem cell plan. Report
Mass. fills in the details on $1B biotech program. Report
Top five regions targeting biotech companies--2007. Report
Boston biotech booming as scientific research flourishes. Report

Suggested Articles

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Broad Institute researchers showed that base-editing the Tmc1 gene preserved hair cells that helped transmit sound in the ears of mice.